During follow-up only four cardiovascular adverse events were regarded by the investigator to be drug-related ( grade 2 lymphostasis and grade 2 lymphoedema , each in one patient in the trastuzumab group , and grade 2 thrombosis and grade 2 deep vein thrombosis , each in one patient in the chemotherapy-alone group ) .